Author

E. Kurth

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

D. A. Ruddy· 2 shared G. Elliott· 2 shared A. C. Palmer· 1 shared A. Kauffmann· 1 shared A. Loo· 1 shared C. Bullock· 1 shared C. Kowal· 1 shared D. Plana· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. A. Ruddy

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia

F. Rago, L. U. Rodrigues, M. Bonney, K. Sprouffske, E. Kurth, G. Elliott, J. Ambrose, P. Aspesi, J. Oborski, J. T. Chen, E. R. McDonald, F. A. Mapa, D. A. Ruddy, A. Kauffmann, T. Abrams, , Z. Jagani

This study shows that dual BRG1/BRM ATPase inhibitors are effective against AML cell lines, revealing broad SWI/SNF dependencies and suggesting therapeutic potential.

bioRxiv · Apr 23, 2021Cancer Biology

Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts

A. C. Palmer, D. Plana, H. Gao, J. M. Korn, G. Yang, J. Green, X. Zhang, R. Velazquez, M. E. McLaughlin, D. A. Ruddy, C. Kowal, J. Goldovitz, C. Bullock, S. Rivera, D. Rakiec, , J. A. Williams

This study identifies biomarker-guided treatment strategies for ovarian cancer using patient-derived tumor xenografts, finding that nearly 90% of PDXs responded to at least one targeted therapy.

bioRxiv · Jan 8, 2020Cancer Biology